Mounjaro Mood Swings: What the Clinical Evidence Actually Shows

What the trial data and official guidance say about Mounjaro and mood swings

The SURMOUNT-1 trial, published in the New England Journal of Medicine, followed 2,539 adults with obesity over 72 weeks and recorded adverse events systematically. Mood swings were not among the commonly reported findings. The adverse event profile was led by gastrointestinal effects: nausea, diarrhoea, vomiting and constipation, particularly around dose increases, mostly mild to moderate and settling within a couple of weeks.

The NHS patient information for tirzepatide similarly does not place mood swings in the common or very common category. The SmPC lists mood-related effects under rare or under investigation rather than as expected occurrences. That matters for anyone reading a forum thread suggesting Mounjaro routinely causes emotional turbulence. It can happen. It doesn't happen to most people.

The MHRA continues to monitor tirzepatide under its Black Triangle (▼) scheme, meaning any new safety signals, including mood-related ones, are reviewed as real-world use data accumulates. If you notice something that feels like a side effect, the right thing to do is report it at yellowcard.mhra.gov.uk and raise it with your prescriber.

Why some people do notice emotional changes in early treatment

Even if tirzepatide doesn't directly cause mood swings through its pharmacological action, the early weeks of treatment involve changes that can affect how someone feels emotionally. Food is bound up with comfort, routine and social life. When appetite drops sharply, some people find their relationship with eating shifts in ways they didn't anticipate. That can surface as irritability, low energy or a flattened mood.

Calorie restriction itself, if significant, can affect mood through reduced carbohydrate and tryptophan availability, both of which influence serotonin. Rapid changes in blood sugar patterns, particularly in people who previously experienced frequent glucose highs and crashes, can also produce emotional variability as the body adjusts. These are physiological explanations that sit alongside the medicine rather than inside it.

Sleep disruption from gastrointestinal side effects in the first few weeks is another factor some people overlook. Poor sleep and mood are closely tied. If nausea is keeping someone awake, irritability the next day isn't surprising. Our overview of Mounjaro side effects covers the broader picture of what to expect during the titration period and how most effects settle with time.

When mood changes warrant closer attention

A question our prescribers hear most weeks is whether what someone is feeling is a normal adjustment or something to act on. The honest answer is that context matters enormously. A few days of feeling a bit flat in week two, alongside nausea, is very different from persistent low mood that doesn't lift, significant anxiety that disrupts daily life, or any thoughts of self-harm.

UK guidance is clear on the latter: these need prompt medical attention, not a wait-and-see approach. The NHS weight-management-injections guidance explicitly flags that patients should seek urgent help for mood changes that are severe or prolonged. If you're unsure whether what you're experiencing falls into that category, err on the side of contacting your prescriber. It's precisely what aftercare exists for.

There's also a subtler pattern worth naming. Some people find that as weight begins to come off, body-image shifts, social dynamics change and old emotional patterns surface. That's not a side effect of the medicine in the pharmacological sense, but it is something that happens during treatment. Organisations like Mind offer resources for anyone navigating emotional health alongside significant life changes, and our page specifically on low mood and Mounjaro goes into more detail on that distinction.

GLP-1 receptors, the brain and what research is still working out

Tirzepatide acts on both GIP and GLP-1 receptors. GLP-1 receptors are present in areas of the brain involved in reward, motivation and mood regulation, including the hypothalamus and limbic structures. This is one reason researchers are actively studying whether GLP-1 receptor agonists might have effects on mental health beyond weight loss, and early findings in other conditions are genuinely interesting.

But interesting research is not the same as established clinical guidance. At present, there is no confirmed evidence that tirzepatide causes mood swings through direct central nervous system action. The question of whether the emotional changes some people report are pharmacological, physiological, psychological or some blend of all three remains open. Anyone with a personal or family history of mood disorders should make sure their prescriber knows this before starting treatment, since it's part of the clinical picture that informs the decision.

For a broader look at tirzepatide's relationship with mood across the clinical literature, or to understand how Mounjaro may affect mood differently across individuals, those pages explore the nuance in more depth. There's also a useful discussion of mood as part of Mounjaro's side-effect profile for anyone comparing experiences across the titration schedule, and our dedicated page on Mounjaro and mood brings together the key questions people ask when they notice emotional shifts during treatment.

Thinking about starting treatment? Our prescribers look at the whole person, not just a BMI number. A free consultation through our treatment page is the first step, and one of our team will review your answers the same day.